Molecular Targeting in Oncology

Herausgegeben:Kaufman, Howard L.; Wadler, Scott; Antman, Karen

• Broschiertes Buch

Produktbeschreibung

In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice.

The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Cancer Drug Discovery and Development
• Verlag: Humana / Humana Press / Springer, Berlin
• Artikelnr. des Verlages: 978-1-61737-653-5
• Softcover reprint of hardcover 1st ed. 2008
• Seitenzahl: 744
• Erscheinungstermin: 26. Mai 2011
• Englisch
• Abmessung: 254mm x 178mm x 40mm
• Gewicht: 1373g
• ISBN-13: 9781617376535
• ISBN-10: 1617376531
• Artikelnr.: 32201792

Autorenporträt

Molecular Targeting in Oncology covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way that readers may begin with chapters that most interest them and work through the rest in the order of their choice. The book is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second describes how clinicians are evaluating targeted therapies in specific organ systems. The third illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more.

Inhaltsangabe

General Strategies for Molecular Targeting in Oncology.- The Cell Cycle.- mTOR.- Ras/Raf/MEK Inhibitors.- 17-AAG.- The Cancer Epigenome.- Molecular Targeting for Specific Disease Sites.- Molecular Targeting in Upper Gastrointestinal Malignancies.- Molecular Targeting of Colorectal Cancer.- Molecular Targeting in Hepatocellular Carcinoma.- Molecularly Targeted Therapy in Pancreatic Cancer.- Untargeted Use of Targeted Therapy.- Renal Cell Carcinoma.- Targeted Therapies for Prostate Cancer.- Molecular Targets in Ovarian Cancer and Endometrial Cancer.- Targeted Therapy For Breast Cancer.- Melanoma.- Classes of Drugs for Molecular Targeting in Oncology.- Antibody Therapy of Cancer.- Nucleic Acid Therapies for Cancer Treatment.- Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy.- Vaccines as Targeted Cancer Therapy.- Cytokine-Based Therapy for Cancer.- Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment.- Specific Drugs for Molecular Targeting in Oncology.- Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations.- Development of a Targeted Treatment for Cancer.- VEGF Inhibition for Cancer Therapy.- Somatostatin Analogue Therapy.- Challenges in Molecular Targeting in Oncology.- Patient Selection for Rational Development of Novel Anticancer Agents.- Clinical Trial Design with Targeted Agents.- How to Define Treatment Success or Failure if Tumors Do Not Shrink.- Molecular Imaging in Oncology.- Combinations of Molecular-Targeted Therapies.- Preclinical Development of Molecularly Targeted Agents in Oncology.